Datafin

Data-driven stock analysis platform for global investors.

Sitemap
HomeScreenerValuationSector Analysis
Resources
LibraryDatafin GuideMetric MethodologyValuation MethodologiesFAQPricingWho Is Datafin?Communication
Legal
Privacy PolicyTerms of UseCookie PolicyKVKK NoticeRefund Policy
Data Sources

Financial data sourced from official regulatory filings and verified market data providers. Metrics calculated using GAAP/IFRS standards.

Disclaimer

The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

Investment decisions involve risk. Verify data independently and consult a licensed advisor when needed.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved.

Last updated: April 2026

SLGC PEER ANALYSIS

Somalogic Inc — metric-by-metric comparison with peers and the industry median

SLGCSomalogic Inc

🇺🇸 USA · NASDAQ · Healthcare · Health Information Services

Value itDuel
PriceFinancialsPeers

Overall Profile & Returns

· Health Information Services

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial Health
SLGCIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
SLGC—PME-31.5%FONET+128.7%
Year-to-Date (YTD)
SLGC-2.7%PME-4.8%FONET+88.2%
1-Year
Split-adjusted
SLGC—PRVA+24.8%DOCS-63.1%WAY-39.3%TXG+199.8%OMCL+44.4%
Year-to-Date (YTD)
SLGC-2.7%PRVA+15.4%DOCS-50.6%WAY-28.4%TXG+139.2%OMCL-5.0%

Key Metric Comparison

P/E

Lower is better
SLGC—PME93.49FONET20.21Median 41.96

ROE

Higher is better
SLGC-23.7%PME76.8%FONET15.6%Median 2.7%

Net Margin

Higher is better
SLGC-159.5%PME97.6%FONET26.0%Median 1.5%

Revenue Growth

Higher is better
SLGC-19.7%PME30.3%FONET53.5%Median 7.1%

P/E

Lower is better
SLGC—PRVA164.54DOCS21.75WAY36.31TXG—OMCL96.75Median 41.96

ROE

Higher is better
SLGC-23.7%PRVA3.1%DOCS19.3%WAY3.6%TXG-3.0%OMCL1.6%Median 2.7%

Net Margin

Higher is better
SLGC-159.5%PRVA1.0%DOCS30.4%WAY10.9%TXG-3.5%OMCL1.7%Median 1.5%

Revenue Growth

Higher is better
SLGC-19.7%PRVA24.7%DOCS13.1%WAY18.6%TXG2.3%OMCL7.9%Median 7.1%

All Metrics

Valuation
MetricSLGCPMEFONETInd. Median
P/E—93.4920.21●41.96
P/B7.2856.422.62●2.50
EV/EBITDA—115.2410.38●16.12
P/S44.2291.215.26●2.35
Financial Health
MetricSLGCPMEFONETInd. Median
Current Ratio17.79●6.222.311.83
Debt/Equity0.6%●1.1%2.5%22.0%
NetDebt/EBITDA3.31-1.16●-0.21-0.01
Profitability
MetricSLGCPMEFONETInd. Median
Net Margin-159.5%97.6%●26.0%1.5%
ROE-23.7%76.8%●15.6%2.7%
ROA-20.8%56.7%●13.2%1.4%
EBITDA Margin-166.7%78.4%●49.6%12.4%
Growth + Dividend
MetricSLGCPMEFONETInd. Median
Rev. Growth-19.7%30.3%53.5%●7.1%
NI Growth—138.8%●26.6%23.6%
Div. Yield—0.3%●0.0%0.7%
Payout—24.5%0.0%9.6%
Valuation
MetricSLGCPRVADOCSWAYTXGOMCLInd. Median
P/E—164.5421.75●36.31—96.7541.96
P/B7.284.764.481.16●6.151.572.50
EV/EBITDA—56.2313.25●14.2748.7315.1416.12
P/S44.221.59●6.613.967.831.612.35
Financial Health
MetricSLGCPRVADOCSWAYTXGOMCLInd. Median
Current Ratio17.79●1.616.091.765.901.461.83
Debt/Equity0.6%●1.2%1.1%37.7%10.0%16.1%22.0%
NetDebt/EBITDA3.31-7.28●-2.783.21-4.91-0.71-0.01
Profitability
MetricSLGCPRVADOCSWAYTXGOMCLInd. Median
Net Margin-159.5%1.0%30.4%●10.9%-3.5%1.7%1.5%
ROE-23.7%3.1%19.3%●3.6%-3.0%1.6%2.7%
ROA-20.8%1.7%16.4%●2.4%-2.4%1.0%1.4%
EBITDA Margin-166.7%2.5%41.3%●35.8%14.6%10.2%12.4%
Growth + Dividend
MetricSLGCPRVADOCSWAYTXGOMCLInd. Median
Rev. Growth-19.7%24.7%●13.1%18.6%2.3%7.9%7.1%
NI Growth—39.3%-12.2%383.6%●—-3.5%23.6%
Div. Yield——————0.7%
Payout——————9.6%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on SLGC

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jun 8, 26. This content is for informational purposes only and is not investment advice.